Skip Navigation

European Journal of Heart Failure 2004 6(3):253-255; doi:10.1016/j.ejheart.2004.01.012
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cleland, J. G.F.
Right arrow Articles by Goode, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cleland, J. G.F.
Right arrow Articles by Goode, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 European Society of Cardiology

Natriuretic peptides for heart failure. Fashionable? Useful? Necessary?

John G.F. Cleland and Kevin Goode

Department of Cardiology, University of Hull, Castle Hill Hospital Cottingham, Kingston-upon-Hull, HU15 5JQ, UK

The concept that natriuretic peptides might prove a useful tool for the evaluation of cardiac disease in the routine clinic or community has been around for at least 20 years [1]. The tools to test this concept are now in the hands of clinicians and need to be properly tested in clinical practice to ensure that they deliver what they promise. Natriuretic peptides will undoubtedly prove similar to all other technologies in that their use will evolve. Assays will be improved to deliver results either faster or more simply or more accurately. The way that the results are interpreted will change as clinicians gain experience and integrate this new information with other data. The technology will surely prove useful in areas previously not considered and will be found inadequate in areas it was expected to succeed. There is no doubt that this technology is fashionable and evolving but has it been proven to be useful in current clinical practice?

Thirty years ago, natriuretic peptides would have been adopted into clinical practice without much further thought, joining the large amount of non-evidence based medicine which employs so much of our time and resources to such questionable effect [2,3]. The evidence for the utility of natriuretic peptides for detecting serious heart disease in breathless patients is almost certainly higher than several more expensive tests, for instance the chest X-ray and, arguably, the echocardiogram [4,5]. However, current practice demands much higher levels of evidence for introducing new diagnostic tools or therapeutic interventions, which is mostly a good thing although it can be frustrating for enthusiasts. It is important that clinicians continually re-examine the tests that they request and treatment that they advise. Removing redundant [2,3] or harmful [6] clinical practices that are done through force of habit is just as important as evaluating new tests and treatments. Harmful, habit-based, rather than innovative, evidence-based, medicine is probably the greater current cost to health-care.

Natriuretic peptides have already shown that they are a useful or even a necessary part of epidemiological studies and clinical trials in advanced heart disease [7–10]. These peptides have consistently been shown to be very powerful prognostic markers [7,10–16]. There is no cheaper or more effective tool for the detection of important structural heart disease and the assessment of prognosis in patients with ischaemic heart disease. There is much more justification for measuring natriuretic peptides than cholesterol in this population, since natriuretic peptides will identify higher risk patients in whom treatment makes a large difference [17]. By contrast, cholesterol is a poor guide to the need for statin therapy and the benefits of statin therapy are comparatively modest, and not even evidence-based in patients with heart failure [17–19]. So, natriuretic peptides are clearly more necessary than cholesterol to guide modern clinical practice.

What is much less clear is the utility of natriuretic peptides for three other obvious purposes. It is not clear what diagnostic role natriuretic peptides have for the assessment of the breathless patient [20–22]. A negative test still leaves the patient with symptoms and the need for a diagnosis. It remains to be seen how many patients end up having an echocardiogram even when natriuretic peptides are normal. Many patients will need further investigation. If natriuretic peptides do have a role in this setting it will be as part of a package of tests. Ultimately, the combination of natriuretic peptides and an imaging test may become the standard investigation in this setting. Left ventricular ejection fraction became a fashionable entry criterion for clinical trials of heart failure in the late 1980s due to the heterogeneity inherent in a clinical diagnosis, which had previously been the main and often sole inclusion criterion, because it was an objective marker of cardiac dysfunction and because it helped identify patients with a poor prognosis [23]. This was an expedient but arbitrary decision. Had natriuretic peptides been widely available, they might have been used instead. Once low ejection fraction became an entry criterion for trials it then became a method of choosing treatment in clinical practice because it was not known if treatment was effective in patients who did not have a low ejection fraction. However, we do not know if ejection fraction is a good way of choosing treatment, we only know it is effective in the group the trials chose to treat. Patients with preserved echocardiographic ejection fraction and raised natriuretic peptides have a worse outcome indicating either the technical inadequacy of the echocardiogram or that this is a group of patients in whom clinical trials to find effective treatments are required [24–27]. Ultimately, further investigation may discover that natriuretic peptides are a better way to choose therapy than an echocardiogram.

Even more complex is the potential role of natriuretic peptides for the monitoring of therapy [28–43]. As natriuretic peptides are prognostically robust it is likely that serial testing carries important information. However, we do not know if we can modify the risk that natriuretic peptides predict. Studies using natriuretic peptides have, so far, generally suggested that doctors do not treat heart failure aggressively enough. Natriuretic peptides are a useful reminder that more treatment is required but perhaps we just need to change practice-habits rather than do another test. There are times when natriuretic peptides could inappropriately suggest that more treatment should be given when a reduction is really required. Studies designed to show that increases and decreases in therapy guided by natriuretic peptides improve outcome compared to a simple, aggressive treatment policy are lacking. This will require large, randomised studies.

This compendium of papers provides fresh and original data on many scientific and clinical aspects of heart failure on this rapidly developing topic. I hope that it will stimulate more research and improvements in clinical care to which the European Journal of Heart Failure is committed.


   References
Top
 References
 

  1. Cleland J.G.F., Ward S., Dutka D., Habib F., Impallomeni M., Morton I.J. Stability of plasma concentrations of N and C-terminal atrial natriuretic peptides at room temperature. Heart (1996) 74(4):410–413.
  2. Cleland J.G.F., Alamgir F., Nikitin N., Clark A., Norell M. What is the optimal medical management of ischaemic heart failure? Prog Cardiovasc Dis (2001) 43(5):433–455.[CrossRef][Web of Science][Medline]
  3. Cleland J.G.F., Freemantle N., Ball S.G., Bonser R.S., Camici P.G., Chattopadhyay S., et al. The heart failure revascularization trial (HEART): rationale design and methodology. Eur J Heart Fail (2003) 5(3):295–303.[Abstract/Free Full Text]
  4. Richards A.M., Nicholls M.G., Espiner E.A., Lainchbury J.G., Troughton R.W., Elliott J., et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation (2003) 107:2786–2792.[Abstract/Free Full Text]
  5. Richards A.M., Nicholls M.G., Yandle T.G., Ikram H., Espiner E.A., Turner J.G., et al. The Christchurch Cardioendocrine Research Group. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. Heart (1999) 81(2):114–120.[Abstract/Free Full Text]
  6. Rogers W.J., Epstein A.E., Arciniegas J.G., Dailey S.M., Kay G.N., Little R.E., et al. Preliminary report: Effect of encainide and flecainide on mortality in a randomised trial of arrhythmia suppression after myocardial infarction. New Engl J Med (1989) 321:406–412.[Abstract]
  7. Hartmann F, Packer M, Coats AJS, et al. NT-proBNP in severe chronic heart failure Rationale, design and preliminary results of the COPERNICUS NT-proBNP sub-study. Eur J Heart Fail 2004 (this issue).
  8. McDonagh TA, Holmer S, Raymond I, Luchner A, Hildebrandt P, Dargie HJ. NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies Eur J Heart Fail 2004 (this issue).
  9. Nielsen OW, Kirk V, Bay M, Boesgaard S, Nielsen H. Value of N-terminal pro Brain Natriuretic Peptide in the elderly: Data from the prospective Copenhagen Hospital Heart Failure Study (CHHF). Eur J Heart Fail 2004 (this issue).
  10. Jernberg T, James S, Lindahl B. NT-proBNP in unstable coronary artery disease: Experiences from the FAST, GUSTO IV, and FRISC II trials. Eur J Heart Fail 2004 (this issue).
  11. Ng L.L., Loke I., Davies J.E., et al. Identification of previously undiagnosed left ventricular systolic dysfunction: community screening using natriuretic peptides and electrocardiography. Eur J Heart Fail (2003) 5(6):775–782.[Abstract/Free Full Text]
  12. Jourdain P., Funck F., Bellorini M., et al. Bedside B-type natriuretic peptide and functional capacity in chronic heart failure. Eur J Heart Fail (2003) 5(2):155–160.[Abstract/Free Full Text]
  13. Yu C.M., Sanderson J.E. Plasma brain natriuretic peptide—an independent predictor of cardiovascular mortality in acute heart failure. Eur J Heart Fail (1999) 1(1):59–65.[Abstract/Free Full Text]
  14. Talwar S., Downie P.F., Squire I.B., Davies J.E., Barnett D.B., Ng L.L. Plasma N-terminal pro BNP and cardiotrophin-1 are elevated in aortic stenosis. Eur J Heart Fail (2001) 3(1):15–19.[Abstract/Free Full Text]
  15. Galvani M, Ferrini D, Ottani F. Natriuretic peptides for risk stratification of patients with acute coronary syndromes. Eur J Heart Fail 2004 (this issue).
  16. Hildebrandt P, Boesen M, Olsen M, Wachtell K, Groenning B. N-terminal pro brain natriuretic peptide in arterial hypertension—a marker for left ventricular dimensions and prognosis. Eur J Heart Fail 2004 (this issue).
  17. Cleland J.G.F., Clark A.L. Delivering the cumulative benefits of triple therapy for heart failure. Too many cooks will spoil the broth. JACC (2003) 42:1226–1233.[Abstract/Free Full Text]
  18. Clark A.L., Cleland J.G.F. Statins for patients with advanced heart disease. Care of the Critically Ill (2003) 19(6):171–173.
  19. Krum H., McMurray J.J. Statins and chronic heart failure: do we need a large-scale outcome trial? JACC (2002) 39(1567):1573.
  20. Coletta A.P., Thackray S., Nikitin N., Cleland J.G. Clinical trials update: highlights of the scientific sessions of The American College of Cardiology : LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL. Eur J Heart Fail (2002) 4(3):381–388.[Abstract/Free Full Text]
  21. Bayes-Genis A, Santalo-Bel M, Zapico-Muniz E, et al. N-terminal pro Brain Natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail 2004 (this issue).
  22. Wu A, Harrison A, Maisel AS. Reduced readmission rate for alternating diagnoses of heart failure and pulmonary disease after implementation of B-type natriuretic peptide testing. Eur J Heart Fail 2004 (This issue).
  23. Marantz P.R., Alderman M., Tobin J.N. Diagnostic Heterogeneity in clinical trials for congestive heart failure. Ann Int Med (1988) 109:55–61.[Abstract/Free Full Text]
  24. Wijbenga A.A., Balk A.H., Jonkman F.A., Boomsma F., Simoons M.L., Man in t Veld A.J. Relation of atrial natriuretic peptides to left ventricular systolic and diastolic function in heart failure. Eur J Heart Fail (1999) 1:51–58.[Abstract/Free Full Text]
  25. Klemola R., Tikkanen I., Vuolteenaho O., Toivonen L., Laine M. Plasma and pericardial fluid natriuretic peptide levels in post-infarction ventricular dysfunction. Eur J Heart Fail (2001) 3(1):21–26.[Abstract/Free Full Text]
  26. Dahlstrom U. Can natriuretic peptides be used for the diagnosis of diastolic heart failure? Eur J Heart Fail 2004 (this issue).
  27. Kirk V, Bay M, Parner J, et al. NT-proBNP and mortality in hospitalised patients with heart failure and preserved vs. reduced systolic function: data from the Copenhagen Hospital Heart Failure Study (CHHF). Eur J Heart Fail 2004 (This issue).
  28. Van Kraaij D.J., Jansen R.W., Sweep F.C., Hoefnagels W.H. Neurohormonal effects of furosemide withdrawal in elderly heart failure patients with normal systolic function. Eur J Heart Fail (2003) 5(1):47–53.[Abstract/Free Full Text]
  29. Groenning B.A., Nilsson J.C., Hildebrandt P.R., et al. Neurohumoral prediction of left-ventricular morphologic response to beta-blockade with metoprolol in chronic left-ventricular systolic heart failure. Eur J Heart Fail (2002) 4(5):635–646.[Abstract/Free Full Text]
  30. Van den Berg M.P., Tjeerdsma G., Jan de Kam P., Boomsma F., Crijns H.J., van Veldhuisen D.J. Longstanding atrial fibrillation causes depletion of atrial natriuretic peptide in patients with advanced congestive heart failure. Eur J Heart Fail (2002) 4(3):255–262.[Abstract/Free Full Text]
  31. Miller W.L., Bailey K.R., Weston S.A., Burnett J.C., Rodeheffer R.J. Hemodynamic and plasma atrial natriuretic peptide responses to acute digitalis therapy in patients with normal and impaired left ventricular function. Eur J Heart Fail (2002) 4(1):63–72.[Abstract/Free Full Text]
  32. Groenning B.A., Nilsson J.C., Sondergaard L., Kjaer A., Larsson H.B., Hildebrandt P.R. Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations. Eur J Heart Fail (2001) 3(6):699–708.[Abstract/Free Full Text]
  33. Hall C. The value of natriuretic peptides for the management of heart failure: current state of play. Eur J Heart Fail (2001) 3(4):395–397.[Free Full Text]
  34. Hurlen M., Hole T., Seljeflot I., Arnesen H. Aspirin does not influence the effect of angiotensin-converting enzyme inhibition on left ventricular ejection fraction 3 months after acute myocardial infarction. Eur J Heart Fail (2001) 3(2):203–207.[Abstract/Free Full Text]
  35. Missouris C.G., Varma C., Ward D., MacGregor G.A. Cardiac peptides and plasma renin activity in acute dilated cardiomyopathy. Eur J Heart Fail (2001) 3(1):109–111.[Free Full Text]
  36. Sigurdsson A., Eriksson S.V., Hall C., Kahan T., Swedberg K. Early neurohormonal effects of trandolapril in patients with left ventricular dysfunction and a recent acute myocardial infarction: a double-blind, randomized, placebo-controlled multicentre study. Eur J Heart Fail (2001) 3(1):69–78.[Abstract/Free Full Text]
  37. McGeoch G., Lainchbury J., Town G.I., Toop L., Espiner E., Richards A.M. Plasma brain natriuretic peptide after long-term treatment for heart failure in general practice. Eur J Heart Fail (2002) 4(4):479–483.[Abstract/Free Full Text]
  38. Cohn J.N. Is there a common mechanism of benefit for effective treatment of heart failure? Eur J Heart Fail (1999) 1:31–34.[Free Full Text]
  39. Houghton A.R., Harrison M., Cowley A.J. Haemodynamic, neurohumoral and exercise effects of losartan vs. captopril in chronic heart failure: results of an ELITE trial substudy. Evaluation of Losartan in the Elderly. Eur J Heart Fail (1999) 1:385–393.[Abstract/Free Full Text]
  40. Dutka D.P., Puri S., Strong R., Cleland J.G. Disruption of the relationship between renin and atrial natriuretic peptide early in the course of ventricular dysfunction. Eur J Heart Fail (1999) 1:371–377.[Abstract/Free Full Text]
  41. Richards M, Troughton RW. NT-proBNP in heart failure: therapy decisions and monitoring. Eur J Heart Fail 2004 (This issue).
  42. Bettencourt P. NT-proBNP and BNP: biomarkers for heart failure management. Eur J Heart Fail 2004 (This issue).
  43. Wu A, Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail 2004 (This issue).

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 HeartHome page
J. G F Cleland, A. Tageldien, N. Maarouf, and N. Hobson
Patients with heart failure who require an implantable defibrillator should have cardiac resynchronisation routinely
Heart, August 1, 2008; 94(8): 963 - 966.
[Full Text] [PDF]

Home page
 Eur J Heart FailHome page
F. I. Parthenakis, A. P. Patrianakos, C. N. Haritakis, E. A. Zacharis, E. G. Nyktari, and P. E. Vardas
NT-proBNP response to dobutamine stress echocardiography predicts left ventricular contractile reserve in dilated cardiomyopathy
Eur J Heart Fail, May 1, 2008; 10(5): 475 - 481.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
J. G.F. Cleland, A. P. Coletta, A. T. Abdellah, M. Nasir, N. Hobson, N. Freemantle, and A. L. Clark
Clinical trials update from the American Heart Association 2006: OAT, SALT 1 and 2, MAGIC, ABCD, PABA-CHF, IMPROVE-CHF, and percutaneous mitral annuloplasty
Eur J Heart Fail, January 1, 2007; 9(1): 92 - 97.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
J. G. Lainchbury, R. W. Troughton, C. M. Frampton, T. G. Yandle, A. Hamid, M. G. Nicholls, and A. M. Richards
NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial
Eur J Heart Fail, August 1, 2006; 8(5): 532 - 538.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
C. Fonseca, A. G. Oliveira, T. Mota, F. Matias, H. Morais, C. Costa, F. Ceia, and on behalf of the EPICA Investigators
Evaluation of the performance and concordance of clinical questionnaires for the diagnosis of heart failure in primary care
Eur J Heart Fail, October 1, 2004; 6(6): 813 - 820.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cleland, J. G.F.
Right arrow Articles by Goode, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cleland, J. G.F.
Right arrow Articles by Goode, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?